Clinical Significance of Fluid-Attenuated Inversion Recovery Vascular Hyperintensities in Transient Ischemic Attack
Background and Purpose—Fluid-attenuated inversion recovery vascular hyperintensity (FVH) is often identified in patients with acute ischemic stroke. The purpose of this study was to determine the clinical significance of FVH in patients with transient ischemic attack (TIA).
Methods—Consecutive inpatients with TIA who underwent MRI within 24 hours of symptom onset were studied. The frequency, relative factors, and time course of FVH were determined.
Results—Of the 202 patients who were enrolled (76 women, mean age, 69.0±13.2 years), FVH was identified in 41 patients (20%). Multivariate analysis showed that atrial fibrillation (odds ratio, 7.14; 95% confidence interval [CI], 2.69–18.1), arterial occlusive lesion (odds ratio, 4.89; 95% CI, 3.03–12.2), and hemiparesis (odds ratio, 2.81; 95% CI, 1.17–7.48) was independently associated with FVH. Of 23 recurrence-free patients with FVH positive undergoing follow-up MRI at a median of 7 days after the onset, FVH was no longer positive in 15 patients (65%). Atrial fibrillation was more common (P=0.027) and arterial occlusive lesion was less common (P<0.001) in patients with transient FVH compared with those with persistent FVH. Within 90 days after the onset, 13 patients developed recurrent TIA or ischemic stroke. After Cox proportional hazard analysis, FVH (hazard ratio, 3.65; 95% CI, 1.09–12.7), arterial occlusive lesion (hazard ratio, 4.15; 95% CI, 1.18–17.1), and coexistence of FVH and arterial occlusive lesion (hazard ratio, 13.9; 95% CI, 3.36–71.0) were significantly associated with recurrent TIA or ischemic stroke.
Conclusions—The presence of FVH early after symptom onset may help to diagnosis TIA, to identify the potential mechanisms of TIA and to predict recurrence risk after a TIA.
- acute stroke
- atrial fibrillation
- fluid-attenuated inversion recovery
- magnetic resonance angiography
- transient ischemic attack
- Received January 11, 2013.
- Revision received March 8, 2013.
- Accepted March 12, 2013.
- © 2013 American Heart Association, Inc.